12 results about "Arthritis gout" patented technology

The present application relates to novel substituted indazoles, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and / or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and / or prophylaxis of diseases, especially for treatment and / or prophylaxis of endometriosis and endometriosis-associated pain and other endometriosis-associated symptoms such as dysmenorrhoea, dyspareunia, dysuria and dyschezia, of lymphoma, rheumatoid arthritis, spondyloarthritis (especially psoriatic spondyloarthritis and Bekhterev's disease), lupus erythematosus, multiple sclerosis, macular degeneration, COPD, gout, fatty liver disorders, insulin resistance, neoplastic disorders and psoriasis.

This invention belongs to the field of biomedical technology, specifically relating to an ointment and its application. The toad oil used in this invention differs significantly in composition from toad venom, and its ointment is effective for various acute and chronic pain conditions. Animal experiments have confirmed that the toad oil ointment significantly reduces the frequency and delays the onset of acetic acid-induced writhing responses, demonstrating a clear analgesic effect. Clinical studies have shown that this ointment is rapidly effective and has a definite therapeutic effect on acute gout attacks, postherpetic neuralgia, and arthritis-related pain and swelling. The formulation effectively improves drug retention and user comfort, and no skin irritation has been observed. This development achieves comprehensive utilization of toad resources, providing an example for the sustainable development of traditional Chinese medicine and the efficient utilization of biological resources.

The present disclosure relates to nucleic acid sequences encoding uricase, polynucleotides, expression cassettes, and delivery vectors comprising the nucleic acid sequences, and methods for delivering or administering the nucleic acid sequences to treat gout, chronic refractory gout, and / or Harrison syndrome.

The present disclosure features chemical entities (e.g., compounds or pharmaceutically acceptable salts thereof) that degrade and / or otherwise modulate (e.g., inhibit) NIMA-related kinase 7 (NEK7). The chemical entities are useful, for example, in treating subjects having one or more conditions or diseases associated with NLRP3 inflammasome activation (e.g., human subjects). The conditions or diseases include, but are not limited to, autoinflammatory and autoimmune conditions (e.g., gout, inflammatory bowel disease, rheumatoid arthritis, multiple sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease), cardiovascular and metabolic conditions (e.g., pericarditis, atherosclerosis, type 2 diabetes mellitus, diabetes mellitus, diabetes mellitus, diabetes mellitus, diabetes mellitus, diabetes mellitus, diabetes mellitus, diabetes mellitus, and the like). ), fibrotic disorders (e.g., interstitial lung disease, chronic kidney disease), hematological disorders (e.g., inflammatory anemia), and ocular disorders (e.g., macular degeneration). In embodiments, although not desired to be constrained theoretically, the chemical entities described herein are believed to directly target (e.g., bind directly) NEK7, thereby altering (e.g., attenuating) the inflammatory response modulated by the NLRP3 inflammasome. The disclosure also features compositions containing the entities as well as methods of using and making the entities.

This invention provides the use of saikosaponin B2 in drug preparation, belonging to the field of natural medicine technology. This invention discovers that saikosaponin B2 has a significant inhibitory effect on NLRP3 inflammasome activation, and can be used to prepare NLRP3 inflammasome inhibitors, which can be used to prepare drugs for treating diseases related to NLRP3 inflammasomes (including gout and gouty arthritis), showing broad application prospects.

The invention aims at providing an acute gouty arthritis diagnosis and treatment preparation based on natural antioxidants and a preparation method and application thereof, and belongs to the technical field of nano biomedical materials.The acute gouty arthritis diagnosis and treatment preparation is self-assembled with spheroidic tea polyphenol and acidified rutin as sources and comprises a polyphenol hydroxyl structure of the natural antioxidants, and the natural antioxidants are added into the polyphenol hydroxyl structure of the natural antioxidants; the nano-probe is formed by coating maleoyl bovine serum albumin (MBSA) and then coupling a NOX2 antibody through an antibody drug coupling technology, and the nano-probe with integrated diagnosis and treatment of acute gouty arthritis is constructed. The nano probe can be used for positioning an acute gouty arthritis part in real time under the guidance of near-infrared region imaging; the probe can directionally remove macrophages and microenvironment high-expression reactive oxygen species (ROS), and the preparation method of the probe is simple and easy to implement.

The invention belongs to the technical field of medicines, and discloses a hydroxime compound derived from an aqueous extract of heads of angelica sinensis, a dehydrated furazan compound of the hydroxime compound, and preparation and application of the hydroxime compound and the dehydrated furazan compound. In particular discloses a hydroxime compound, a dehydrated furazan compound thereof, pharmaceutically acceptable salts of the dehydrated furazan compound and a pharmaceutical composition of the dehydrated furazan compound. The invention also discloses application of the compound in preparation of medicines for treating arthritis, asthma, chronic obstructive pneumonia, pneumonia, cystic fibrosis, diabetes, obesity, hypercholesterolemia, contact dermatitis, psoriasis, atopic dermatitis, stasis dermatitis, seborrheic dermatitis, neurodermatitis and the like, inflammatory enteritis, multiple sclerosis, Parkinson's disease, cardiovascular disease, autoimmune disease, gout and the like. The invention also relates to applications in medicines or health-care products for treating hyperuricemia and cancers. Activity evaluation of a cell model for starting reporter gene expression by using an NF-kappa B reaction element proves that the compound can significantly inhibit NF-kappa B induced transcriptional regulation and is expected to become a therapeutic drug for treating the various diseases.

The invention provides a ramulus uncariae cum uncis and radix clematidis gout health-care compound extracting solution quality evaluation system and method, and relates to the technical field of health-care product quality evaluation.The ramulus uncariae cum uncis and radix clematidis gout health-care compound extracting solution quality evaluation system comprises a calculation module used for determining a multi-dimensional space vector field in a space density distribution structure, measuring orientations of a rhynchophylline characteristic absorption peak, an isorhynchophylline characteristic absorption peak and a clematis saponin characteristic absorption peak are determined in a vector field, and a spectral response calibration coefficient is generated by calculating spatial curvature integral and vector field direction parameters among the three measuring orientations. According to the method, near infrared spectrum data is combined with spatial density distribution and a multi-dimensional vector field to generate a spectral response calibration coefficient, a partial least square quantitative model is optimized, a quality marker is fused to predict a content comparison result and a spectrogram similarity, and comprehensive judgment of the quality of the uncaria rhynchophylla and radix clematidis gout health-care compound extracting solution is realized.

The invention provides an application of saikoside B2 in preparation of medicines, and belongs to the technical field of natural medicines. The saikoside B2 is found to have a remarkable effect of inhibiting activation of the NLRP3 inflammasome, can be used for preparing an NLRP3 inflammasome inhibitor, is used for preparing a medicine for treating diseases (including gout and gouty arthritis) related to the NLRP3 inflammasome, and has a wide application prospect.

The invention aims to provide a preparation method and application of a biomass-based gouty arthritis imaging and treatment integrated nano capsule, and belongs to the technical field of nano biomedical materials.The preparation method comprises the steps that nano particles are purified and extracted from a natural soybean fermentation product, the nano particles are externally wrapped with apotransferrin, and after freeze-drying, the nano capsule is prepared into the gouty arthritis imaging and treatment integrated nano capsule. The inner layer of the capsule shell is coated with pH response type hydrogel, and the gouty arthritis imaging and treatment integrated nano capsule is successfully prepared. After oral administration, the nano-capsule effectively releases nano-particles in the nano-capsule into intestinal tracts by using the pH-responsive hydrogel, enters in-vivo blood circulation through apotransferrin receptors in targeted intestinal tracts, then is caught by inflammatory cells through leakage vascular extravasation, and passively gathers at gouty arthritis parts; the inflammatory microenvironment of gouty arthritis is effectively improved by utilizing catalase-like activity, uricase-like activity and iron ion chelating ability of the nanoparticles.

1. Name of the product in this design: Gout lithotripter. 2. Purpose of this design: To remove tophi. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key points: 3D view 1.